Cellectis S.A. Stock News

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, Fra

NEW YORK, 28 juin 2022 (GLOBE NEWSWIRE) -- L’Assemblée Générale à caractère mixte de Cellectis (Euronext Growth : ALCLS – Nasdaq : CLLS) s’est tenue le mardi 28 juin 2022 à Paris, au si�

Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving

NEW YORK, 23 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de

The company bucked the recent downward trend for biotech companies.

The company bucked the recent downward trend for biotech companies.

Upgrades According to William Blair, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. At the moment, the stock has a 52-week-high of $55.87 and a 52-week-low of $16.38. O

NEW YORK, 16 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génom

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to

Cellectis S.A. (NASDAQ:CLLS ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Browns

•  Les données précliniques du produit candidat UCART20x22 présentées à l’AACR établissent une preuve de concept avec une solide activité anti-tumorale in vitro et in vivo